These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17485917)

  • 1. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
    Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
    J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
    Yasuda N; Nagakura T; Inoue T; Yamazaki K; Katsutani N; Takenaka O; Clark R; Matsuura F; Emori E; Yoshikawa S; Kira K; Ikuta H; Okada T; Saeki T; Asano O; Tanaka I
    Eur J Pharmacol; 2006 Oct; 548(1-3):181-7. PubMed ID: 16973152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
    Yamazaki K; Yasuda N; Inoue T; Yamamoto E; Sugaya Y; Nagakura T; Shinoda M; Clark R; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2007 Feb; 320(2):738-46. PubMed ID: 17093132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y; Kamoshima H; Nakamura A; Nomoto H
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.
    Kusunoki Y; Katsuno T; Myojin M; Miyakoshi K; Ikawa T; Matsuo T; Ochi F; Tokuda M; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2013; 60(4):431-9. PubMed ID: 23220949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
    Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T
    Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination therapy with insulin and alpha-glucosidase inhibitor].
    Watanabe K; Kawamori R
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():447-51. PubMed ID: 12387032
    [No Abstract]   [Full Text] [Related]  

  • 17. Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats.
    Tanaka-Amino K; Hatakeyama Y; Takakura S; Mutoh S
    Pharmacol Res; 2009 Oct; 60(4):264-9. PubMed ID: 19520592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
    Yamada K
    Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Glucosidase inhibitory effect of resveratrol and piceatannol.
    Zhang AJ; Rimando AM; Mizuno CS; Mathews ST
    J Nutr Biochem; 2017 Sep; 47():86-93. PubMed ID: 28570943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Nakamura J
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():457-61. PubMed ID: 15779422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.